Abstract
Mechanosensitivity is a property common to many cell types. Because channels gated by mechanical stimuli (mechanosensitive channels, MSCs) are implicated in many normal and pathological cellular responses, they present a valid target for therapeutic agents. However the process of mechanotranduction, the structure, function and pharmacology of eukaryotic MSCs are not well understood and matching experimental and in vivo stimuli is difficult. With respect to the pharmacology of these channels, a further complication arises because agents that modulate the activity of MSCs may not even bind to the channel itself, but may cause their effects by changing the properties of the tension-sensing lipid bilayer and/or cytoskeleton. MSCs in the myocardium are discussed in the context of their probable role in the generation of stretch-activated arrhythmias. The actions of the three most prominent agents used to study MSCs in the heart, the lanthanide gadolinium, the aminoglycosidic antibiotic streptomycin, and a peptide toxin isolated from tarantula venom, GsMTx- 4, are compared. While all three can prevent mechanically-induced cardiac arrhythmias in experimental situations, only GsMTx-4 seems to have the potential as a novel therapeutic agent for the targeting of arrhythmias provoked by MSCs.
Keywords: Mechanosensitive channels, myocardium, gadolinium, streptomycin, GsMTx-4, cardiac arrhythmias
Current Pharmaceutical Design
Title: Mechanosensitive Channels: Therapeutic Targets in the Myocardium?
Volume: 12 Issue: 28
Author(s): Ed White
Affiliation:
Keywords: Mechanosensitive channels, myocardium, gadolinium, streptomycin, GsMTx-4, cardiac arrhythmias
Abstract: Mechanosensitivity is a property common to many cell types. Because channels gated by mechanical stimuli (mechanosensitive channels, MSCs) are implicated in many normal and pathological cellular responses, they present a valid target for therapeutic agents. However the process of mechanotranduction, the structure, function and pharmacology of eukaryotic MSCs are not well understood and matching experimental and in vivo stimuli is difficult. With respect to the pharmacology of these channels, a further complication arises because agents that modulate the activity of MSCs may not even bind to the channel itself, but may cause their effects by changing the properties of the tension-sensing lipid bilayer and/or cytoskeleton. MSCs in the myocardium are discussed in the context of their probable role in the generation of stretch-activated arrhythmias. The actions of the three most prominent agents used to study MSCs in the heart, the lanthanide gadolinium, the aminoglycosidic antibiotic streptomycin, and a peptide toxin isolated from tarantula venom, GsMTx- 4, are compared. While all three can prevent mechanically-induced cardiac arrhythmias in experimental situations, only GsMTx-4 seems to have the potential as a novel therapeutic agent for the targeting of arrhythmias provoked by MSCs.
Export Options
About this article
Cite this article as:
White Ed, Mechanosensitive Channels: Therapeutic Targets in the Myocardium?, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522083
DOI https://dx.doi.org/10.2174/138161206778522083 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Late-Onset Glycogen Storage Disease Type 2
Current Molecular Medicine MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Vascular Pharmacology Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues
Current Vascular Pharmacology Renal Ischemia: How Commonly Does it Cause Renal Failure?
Current Hypertension Reviews Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Acute Kidney Injury after Complex Endovascular Aneurysm Repair
Current Pharmaceutical Design Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Patterns of Acute Intracranial Hemorrhage in Adult Patients with Bilateral and Unilateral Moyamoya Disease
Current Neurovascular Research Anti-epileptic Drug (AED) Use in Subarachnoid Hemorrhage (SAH) and Intracranial Hemorrhage (ICH)
Current Pharmaceutical Design